遗传变异对南非复发性肺结核患者利福平和异烟肼药代动力学的影响。
Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis.
机构信息
Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.
Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
出版信息
Pharmacogenomics. 2019 Mar;20(4):225-240. doi: 10.2217/pgs-2018-0166. Epub 2019 Feb 15.
Abstract
AIM
We report the prevalence and effect of genetic variability on pharmacokinetic parameters of isoniazid and rifampicin.
MATERIALS & METHODS: Genotypes for SLCO1B1, NAT2, PXR, ABCB1 and UGT1A genes were determined using a TaqMan Genotyping OpenArray™. Nonlinear mixed-effects models were used to describe drug pharmacokinetics.
RESULTS
Among 172 patients, 18, 43 and 34% were classified as rapid, intermediate and slow NAT2 acetylators, respectively. Of the 58 patients contributing drug concentrations, rapid and intermediate acetylators had 2.3- and 1.6-times faster isoniazid clearance than slow acetylators. No association was observed between rifampicin pharmacokinetics and SLCO1B1, ABCB1, UGT1A or PXR genotypes.
CONCLUSION
Clinical relevance of the effects of genetic variation on isoniazid concentrations and low first-line tuberculosis drug exposures observed require further investigation.
摘要
目的
我们报告异烟肼和利福平的药代动力学参数的遗传变异性的流行率和影响。
材料与方法
使用 TaqMan 基因分型开放式阵列，确定 SLCO1B1、NAT2、PXR、ABCB1 和 UGT1A 基因的基因型。采用非线性混合效应模型描述药物的药代动力学。
结果
在 172 名患者中，分别有 18%、43%和 34%被归类为快速、中间和缓慢 NAT2 乙酰化酶。在 58 名提供药物浓度的患者中，快速和中间乙酰化酶的异烟肼清除率比缓慢乙酰化酶快 2.3 倍和 1.6 倍。未观察到 SLCO1B1、ABCB1、UGT1A 或 PXR 基因型与利福平药代动力学之间存在相关性。
结论
需要进一步研究遗传变异对异烟肼浓度和一线抗结核药物低暴露的影响的临床相关性。
相似文献
1
Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis.
Pharmacogenomics. 2019 Mar;20(4):225-240. doi: 10.2217/pgs-2018-0166. Epub 2019 Feb 15.
2
Effect of Genetic Variation of on Isoniazid and and on Rifampin Pharmacokinetics in Ghanaian Children with Tuberculosis.
Antimicrob Agents Chemother. 2018 Feb 23;62(3). doi: 10.1128/AAC.02099-17. Print 2018 Mar.
3
Genetic and clinical predictors of rifapentine and isoniazid pharmacokinetics in paediatrics with tuberculosis infection.
J Antimicrob Chemother. 2024 Jun 3;79(6):1270-1278. doi: 10.1093/jac/dkae059.
4
Effect of genetic variation in UGT1A and ABCB1 on moxifloxacin pharmacokinetics in South African patients with tuberculosis.
Pharmacogenomics. 2018 Jan;19(1):17-29. doi: 10.2217/pgs-2017-0144. Epub 2017 Dec 6.
5
Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses.
J Antimicrob Chemother. 2014 May;69(5):1339-49. doi: 10.1093/jac/dkt524. Epub 2014 Jan 31.
6
Full-gene sequencing analysis of NAT2 and its relationship with isoniazid pharmacokinetics in Venezuelan children with tuberculosis.
Pharmacogenomics. 2014 Feb;15(3):285-96. doi: 10.2217/pgs.13.230.
7
Variability in plasma rifampicin concentrations and role of , , and genotypes in Ethiopian patients with tuberculosis.
Infect Dis (Lond). 2024 Apr;56(4):308-319. doi: 10.1080/23744235.2024.2309348. Epub 2024 Feb 5.
8
Influence of N-acetyltransferase 2 (NAT2) genotype/single nucleotide polymorphisms on clearance of isoniazid in tuberculosis patients: a systematic review of population pharmacokinetic models.
Eur J Clin Pharmacol. 2022 Oct;78(10):1535-1553. doi: 10.1007/s00228-022-03362-7. Epub 2022 Jul 19.
9
Efficacy, safety, and pharmacokinetics of isoniazid affected by NAT2 polymorphisms in patients with tuberculosis: A systematic review.
Clin Transl Sci. 2024 Apr;17(4):e13795. doi: 10.1111/cts.13795.
10
The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Coinfected Patients in Uganda in the SOUTH Study.
Clin Pharmacol Ther. 2019 Aug;106(2):450-457. doi: 10.1002/cpt.1403. Epub 2019 Mar 29.
引用本文的文献
1
Genetic polymorphisms and adverse reactions to antituberculosis therapy.
Pharmacogenomics. 2025 Apr-Apr;26(5-6):207-221. doi: 10.1080/14622416.2025.2509479. Epub 2025 Jun 20.
2
Parametric Population Pharmacokinetics Model Repository of Rifampicin: Model-Informed Individualized Therapy.
Clin Pharmacol. 2025 Apr 15;17:49-78. doi: 10.2147/CPAA.S502272. eCollection 2025.
3
State of the art of real-life concentration monitoring of rifampicin and its implementation contextualized in resource-limited settings: the Tanzanian case.
JAC Antimicrob Resist. 2024 Nov 14;6(6):dlae182. doi: 10.1093/jacamr/dlae182. eCollection 2024 Dec.
4
Machine Learning Approach in Dosage Individualization of Isoniazid for Tuberculosis.
Clin Pharmacokinet. 2024 Jul;63(7):1055-1063. doi: 10.1007/s40262-024-01400-4. Epub 2024 Jul 11.
5
The impact of alcohol and illicit substance use on the pharmacokinetics of first-line TB drugs.
J Antimicrob Chemother. 2024 Aug 1;79(8):2022-2030. doi: 10.1093/jac/dkae206.
6
Assessment of body mass-related covariates for rifampicin pharmacokinetics in healthy Caucasian volunteers.
Eur J Clin Pharmacol. 2024 Sep;80(9):1271-1283. doi: 10.1007/s00228-024-03697-3. Epub 2024 May 9.
7
Exploring Variability in Rifampicin Plasma Exposure and Development of Anti-Tuberculosis Drug-Induced Liver Injury among Patients with Pulmonary Tuberculosis from the Pharmacogenetic Perspective.
Pharmaceutics. 2024 Mar 12;16(3):388. doi: 10.3390/pharmaceutics16030388.
8
Model-Informed Precision Dosing of Isoniazid: Parametric Population Pharmacokinetics Model Repository.
Drug Des Devel Ther. 2024 Mar 14;18:801-818. doi: 10.2147/DDDT.S434919. eCollection 2024.
9
Variability in plasma rifampicin concentrations and role of , , and genotypes in Ethiopian patients with tuberculosis.
Infect Dis (Lond). 2024 Apr;56(4):308-319. doi: 10.1080/23744235.2024.2309348. Epub 2024 Feb 5.
10
Molecular determinants of multidrug-resistant tuberculosis in Sierra Leone.
Microbiol Spectr. 2024 Mar 5;12(3):e0240523. doi: 10.1128/spectrum.02405-23. Epub 2024 Jan 30.
本文引用的文献
1
The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugs.
Tuberculosis (Edinb). 2018 Jan;108:77-82. doi: 10.1016/j.tube.2017.11.004. Epub 2017 Nov 7.
2
Effect of genetic variation in UGT1A and ABCB1 on moxifloxacin pharmacokinetics in South African patients with tuberculosis.
Pharmacogenomics. 2018 Jan;19(1):17-29. doi: 10.2217/pgs-2017-0144. Epub 2017 Dec 6.
3
Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis.
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.00490-17. Print 2017 Aug.
4
Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis.
Antimicrob Agents Chemother. 2017 Jun 27;61(7). doi: 10.1128/AAC.00210-17. Print 2017 Jul.
5
Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis.
Clin Infect Dis. 2017 May 15;64(10):1350-1359. doi: 10.1093/cid/cix158.
6
Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB.
J Antimicrob Chemother. 2017 May 1;72(5):1441-1449. doi: 10.1093/jac/dkx004.
7
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
Lancet Infect Dis. 2017 Jan;17(1):39-49. doi: 10.1016/S1473-3099(16)30274-2. Epub 2016 Oct 26.
8
Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model.
PLoS Med. 2017 Jan 3;14(1):e1002202. doi: 10.1371/journal.pmed.1002202. eCollection 2017 Jan.
9
The challenges of pharmacokinetic variability of first-line anti-TB drugs.
Expert Rev Clin Pharmacol. 2017 Jan;10(1):47-58. doi: 10.1080/17512433.2017.1246179. Epub 2016 Nov 2.
10
SLCO1B1 gene polymorphisms do not influence plasma rifampicin concentrations in a South Indian population.
Int J Tuberc Lung Dis. 2016 Sep;20(9):1231-5. doi: 10.5588/ijtld.15.1007.
Zotero 插件